POPULATION SCREENING FOR CHRONIC DISEASE MAXIMISING BENEFITS, MINIMISING HARMS Public Health Association of Australia (PHAA) hold conference on current and future advances in population screening
With
Adjunct Professor Terry Slevin, Chief Executive Officer
Public Health Association of Australia
Australian Health Journal Segment
Filmed in Sydney | March 2025
Population screening is an important contributor to advancing health outcomes through the early detection of and successful intervention for chronic disease. The evolution of science, technology and evidence relating to diseases which are or may be amenable to a population screening approach deserve broad discussion and the sharing of expertise and evidence. They also warrant close scrutiny in context of health policy and health resource allocation considerations.
There are established (and proposed) screening programs relevant to a range of diseases, notably breast, cervix, bowel cancer, and more recently for skin and lung cancer screening. There are a number of other chronic diseases where as new technologies are emerging and evidence is being gathered to support organised screening, (including but not limited to diabetes, CKD, MAFLD as well as cardiovascular and other risk assessment for primary prevention in general practice.
Population-based criteria for screening, based on WHO criteria and the Australian Population Based Screening Framework, aim to ensure that the benefits of screening outweigh and minimise any potential harms. These criteria are well understood by those involved in established screening programs and advocates for emerging screening programs are keen to learn from past experience how to compile evidence, design, implement and monitor programs, as well as ensure equitable participation. Similarly, there is much to learn from emerging programs and new technologies for those involved in established programs where adopting advances in evidence and technology can be challenging and perceived as slower.
In March, Public Health Association of Australia (PHAA) convened Screening Conference Conference 2025 with the theme of ‘Population Screening for Chronic Disease – Maximising Benefits, Minimising Harms’.
The conference provided opportunities for attendees to exchange information on population screening and learn from each other’s experience, across a range of disciplines. Those in attendance and presenting came from research, society, Government, program delivery, policy, consumers and clinicians.
Source: Adapted from Screening 2025 Conference website (PHAA operated)
-
Cardiologist broadens Tasmania’s surgical abilities
Dr Heath Adams is a Tasmanian born, bred and educated interventional and structural cardiologist who works at Hobart Private and Royal Hobart Hospital and is a researcher through the Menzies Research Institute.
Dr Adams clinical interest and expertise is in the management of aortic stenosis, valvular heart disease and acute coronary syndromes. Dr Adams performs coronary interventions including stenting, and structural heart interventions including TAVI, mitral edge to edge repair, mitral valve replacement and left atrial appendage closure. In 2020, Heath performed the first TAVI in Tasmania, is the clinical lead for the local program at the Royal Hobart Hospital and is a nationally accredited TAVI practitioner.
-
25 years of non-indexation of nuclear medicine impeding access & affordability
The President of the Australasian Association of Nuclear Medicine Specialists (AANMS), Associate Professor Sze Ting Lee spoke with Australian Health Journal about the following:
Usual levels of nuclear medicine services in Australia each year
Current levels of nuclear medicine services in Australia
How changing demographics in people moving to regional areas has impacted access to nuclear medicine services
The nuclear medicine workforce including trainees
The key recommendations from the pre-budget submissionIn the lead up to the Australian Federal Budget in May 2023, Australian Health Journal reached out to peak health industry bodies to hear about their priorities, either noted in pre-budget submissions lodged with Federal Government in January 2023 or in recent forums such as the Strengthening Medicare Taskforce.
-
Improved treatment in advanced-stage Hodgkin lymphoma
A global clinical trial successfully reduced toxicity and side effects in advanced stage Hodgkin lymphoma patients by using a modified treatment regimen.
Australian Health Journal spoke with Professor Mark Hertzberg in his role in the ALLG HD10 Clinical Trial and as a former Chair of the Scientific Advisory Committee of the Australasian Leukaemia & Lymphoma Group (ALLG), an organisation involved in improving the treatments and lives of blood cancer patients.
